EMA Expanding Use Of Early Background Summaries To Support Initial Drug Evaluations
Executive Summary
The European Medicines Agency is expanding an initiative in which its product team summarizes critical background information about new drugs to help the agency’s scientific committees assess initial marketing authorization application.